Protagonist Therapeutics Enters Material Definitive Agreement
Ticker: PTGX · Form: 8-K · Filed: Jan 31, 2024 · CIK: 1377121
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-action, partnership
TL;DR
**Protagonist Therapeutics just signed a big deal, watch for details!**
AI Summary
Protagonist Therapeutics, Inc. filed an 8-K on January 31, 2024, to report an "Entry into a Material Definitive Agreement." This filing indicates that the company has entered into a significant new contract or partnership, which could impact its future operations and financial performance. For investors, this matters because such agreements often signal new revenue streams, strategic collaborations, or changes in business direction, potentially affecting the stock's valuation.
Why It Matters
This filing signals a new, significant business agreement for Protagonist Therapeutics, which could lead to new opportunities or obligations that impact its financial health and stock price.
Risk Assessment
Risk Level: medium — The filing indicates a material agreement but lacks specific details, creating uncertainty about its financial impact and potential risks or benefits.
Analyst Insight
A smart investor would monitor Protagonist Therapeutics for subsequent filings or press releases that provide specific details about the "Material Definitive Agreement" to assess its potential impact on the company's financials and future prospects before making any investment decisions.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 31, 2024 (date) — date of earliest event reported
- Delaware (company) — state of incorporation for Protagonist Therapeutics, Inc.
- 001-37852 (company) — Commission File Number for Protagonist Therapeutics, Inc.
- 98-0505495 (company) — IRS Employer Identification No. for Protagonist Therapeutics, Inc.
Forward-Looking Statements
- Protagonist Therapeutics will release further details about the material definitive agreement. (Protagonist Therapeutics, Inc.) — high confidence, target: Q1 2024
- The stock price of Protagonist Therapeutics will experience volatility as investors await details of the agreement. (Protagonist Therapeutics, Inc.) — medium confidence, target: February 2024
FAQ
What is the specific nature of the "Material Definitive Agreement" mentioned in the filing?
The filing states "Entry into a Material Definitive Agreement" but does not provide specific details about the nature of the agreement, such as the parties involved, the terms, or the financial implications. It only indicates that such an agreement was entered into on January 31, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 31, 2024, as stated under "Date of Report (Date of earliest event reported): January 31, 2024."
What is the business address of Protagonist Therapeutics, Inc. as listed in the filing?
The business address of Protagonist Therapeutics, Inc. is 7707 Gateway Blvd., Suite 140, Newark, California 94560-1160, with a business phone number of (510) 474-0170.
Under which SEC Act is this current report filed?
This current report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Central Index Key (CIK) for Protagonist Therapeutics, Inc.?
The Central Index Key (CIK) for Protagonist Therapeutics, Inc. is 0001377121, as found in the COMPANY DATA section of the filing.
Filing Stats: 1,679 words · 7 min read · ~6 pages · Grade level 16.8 · Accepted 2024-01-31 16:05:16
Key Financial Figures
- $0.00001 — h registered Common Stock, par value $0.00001 PTGX The Nasdaq Stock Market LLC
- $300 million — o pay the Company an upfront payment of $300 million within 30 days after the Effective Date
- $330 million — pany for Licensed Products of (i) up to $330 million if the Company does not exercise an Opt
- $975 million — Profit-Share Territory; and (ii) up to $975 million if the Company exercises the Full Opt-o
- $200 million — below), the Company will receive: (a) a $200 million payment following its exercise of the F
Filing Documents
- tm244678d1_8k.htm (8-K) — 37KB
- 0001104659-24-008787.txt ( ) — 209KB
- ptgx-20240131.xsd (EX-101.SCH) — 3KB
- ptgx-20240131_lab.xml (EX-101.LAB) — 33KB
- ptgx-20240131_pre.xml (EX-101.PRE) — 22KB
- tm244678d1_8k_htm.xml (XML) — 4KB
01. Entry into a Material
Item 1.01. Entry into a Material Definitive Agreement Collaboration and License Agreement On January 31, 2024, Protagonist Therapeutics, Inc. (the " Company ") entered into a License and Collaboration Agreement (the " Collaboration Agreement ") with Takeda Pharmaceuticals USA, Inc. (" Takeda ") for the development, manufacture and commercialization of the Company's rusfertide product candidate (" Rusfertide ") and other specified second-generation injectable hepcidin mimetic compounds (the " Licensed Products "). The Collaboration Agreement will become effective (the " Effective Date ") upon the receipt of clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Collaboration and Licenses . The Company and Takeda have agreed that the parties will, as further described below, jointly develop and commercialize the Licensed Products in the United States (the " Profit-Share Territory ") and that Takeda solely and exclusively will develop and commercialize the Licensed Products in all other countries (the " Takeda Territory "). Each of the Company and Takeda is obligated to use commercially reasonable efforts to develop and commercialize at least one Licensed Product in the Profit-Share Territory, and Takeda is also obligated to use commercially reasonable efforts to develop and commercialize at least one Licensed Product in major regions of the Takeda Territory. The Company and Takeda have agreed to share costs of the development, manufacture and commercialization activities for the Licensed Products under the Collaboration Agreement in the Profit-Share Territory, provided that (i) the Company will lead, and will be responsible for its costs associated with, completion of the ongoing Phase 3 VERIFY program evaluating Rusfertide for the treatment of Polycythemia Vera (the " VERIFY Program "); (ii) Takeda will lead, and will be responsible for its costs associated with, pre-commercialization activities related to Rusfertide in the Profit-Share Terri